May 1, 2018

Transcatheter Therapy for Mitral Valve Bioprosthesis Failure: Who’s a Good Candidate?

Analysis of large re-replacement surgery cohort pinpoints key characteristics

18-HRT-4525-Gillinov-AATS-CQD

Advanced symptoms, renal dysfunction and heart block are the leading risk factors to consider when selecting candidates to undergo transcatheter valve-in-valve therapy for a failed bioprosthetic mitral valve.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

So conclude the authors of a large Cleveland Clinic analysis of contemporary outcomes of mitral valve re-replacement surgery for bioprosthetic structural valve deterioration conducted to set a benchmark for transcatheter therapies.

“Data from the STS Adult Cardiac Surgery Database show an increasing shift toward use of bioprosthetic valves and a decrease in the age of patients undergoing mitral valve replacement,” says A. Marc Gillinov, MD, Chair of Thoracic and Cardiovascular Surgery at Cleveland Clinic and a coauthor of the study, which was presented at the AATS annual meeting on May 1. “These trends inevitably will lead to more patients developing structural valve deterioration. As enthusiasm grows for valve-in-valve transcatheter mitral valve replacement for degenerated bioprostheses in highly selected patients, establishing a framework for outcomes and risk factors based on surgical mitral valve re-replacements is important.”

27-year single-center analysis

To that end, Dr. Gillinov and colleagues reviewed all 1,090 mitral valve re-replacement surgeries performed at Cleveland Clinic from January 1990 to January 2017. Of these, 462 surgeries involved explantation of a bioprosthetic valve for structural deterioration, which was the focus of the study.

Among these 462 cases, the dominant characteristic of the deterioration was regurgitation in 81 percent of cases, with stenosis involved in 35 percent of cases. Most patients were symptomatic, and 49 percent were in New York Heart Association (NYHA) functional class III or IV. Mean patient age at mitral valve re-replacement was 67 years, and the median interval between bioprosthesis implantation and re-replacement was 10 years.

End points included in-hospital mortality and morbidity as well as time-related mortality. Risk factors were assessed using multivariable nonproportional hazards analysis. Median follow-up was 5.7 years, with 10 percent of survivors followed at least 19 years.

Advertisement

Results: Mortality and risk factors

Hospital mortality for mitral valve re-replacement was 6.1 percent. Long-term survival rates were as follows:

  • 88 percent at one year after re-replacement
  • 72 percent at five years
  • 49 percent at 10 years
  • 29 percent at 15 years

Leading risk factors for all-cause mortality early after re-replacement were as follows:

  • Higher preoperative NYHA class
  • Preoperative renal dysfunction
  • Preoperative complete heart block

Leading risk factors for all-cause long-term mortality were as follows:

  • Older age
  • Higher number of prior cardiac operations
  • Prior myocardial infarction

The findings in context

Dr. Gillinov notes that surgical re-replacement has been the standard treatment strategy for bioprosthetic mitral valves that develop severe stenosis or regurgitation due to prosthesis deterioration. He adds, however, that this approach carries heightened risks in patients with significant comorbidities or in poor clinical condition, as well as when procedural complexity is high.

“Transcatheter valve-in-valve therapies are evolving as an alternative to surgical re-replacement in patients who are at high surgical risk,” he says. “We believe the results from our surgical analysis help set a benchmark for transcatheter therapy as it continues to evolve. Our findings align with previous reports and indicate that risk factors associated with early mortality — higher NYHA class, renal dysfunction and heart block — are useful for identifying high-risk patients who may be candidates for transcatheter therapies.”

Advertisement

The study will be submitted for publication soon.

Image at top: 3D transesophageal echo view of an open mitral valve following valve-in-valve placement. Reprinted from Cleveland Clinic Journal of Medicine (2016;83[suppl2]:S10-S17).

Related Articles

photo of intubated elderly woman in hospital bed
February 23, 2024
Proteomic Study Characterizes Markers of Frailty in Cardiovascular Disease and Their Links to Outcomes

Findings support emphasis on markers of frailty related to, but not dependent on, age

GettyImages-1252287413 [Converted]
September 8, 2023
Black Residents of Historically Redlined Areas Have Increased Heart Failure Risk

Large database study reveals lingering health consequences of decades-old discrimination

23-HVI-4172009 CQD 650×450-2
August 29, 2023
Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

21-HVI-2577809_septal-myectomy-LVOTO-repair_650x450
January 6, 2022
Study Confirms Quality-of-Life Benefits of Myectomy in Obstructive HCM

Prospective SPIRIT-HCM trial demonstrates broad gains over 12-month follow-up

21-HVI-2211308 gender-scales_650x450
August 10, 2021
8 Ways to Increase Women’s Participation in Cardiovascular Trials

An ACC committee issues recommendations to accelerate sluggish progress

20-HVI-1998312_carotid-endarterectomy_650x450
December 4, 2020
Carotid Endarterectomy and the High-Risk Patient

Review of our recent experience shows it’s still a safe option

20-HVI-2006253-artificial-intelligence-heart-research_650x450
November 30, 2020
AI Looms Large in New Studies of Heart Transplant Rejection and Noncompaction Cardiomyopathy

Machine learning may improve risk prediction and guide therapy

20-HVI-1998310_aortic-stenosis_650x450
November 19, 2020
Recent U.S. Progress Against Aortic Stenosis Mortality Has Not Been Uniform

Nationwide database study finds racial and regional variations

Ad